NMDA receptor antagonists mitigate COVID-19-induced neuroinflammation and improve survival in a mouse model

Антагонисты рецепторов NMDA ослабляют нейровоспаление, вызванное COVID-19, и повышают выживаемость в модели на мышах
Kenneth E. Palmer, Jon D. Gabbard, Linda P. Dwoskin, Jill R Turner, Emily R. Prantzalos, Jane P Chesser, Judy Songrady Logan, Kristen A. McLaurin, Charles D. Anderson, William E. Severson, Bobbi Jo Mullins
2025-06-04

COVID-19 neuroinflammationMemantineMouse modelNMDA receptor antagonistsSARS-CoV-2
The virus known to cause COVID-19, SARS-CoV-2, exhibits severe and complex neurological symptoms. These effects may be attributed to a virus-induced neuroinflammatory environment, warranting exploration of the respiratory centers of the brain, namely the pons and medulla, specifically in relation to neuroinflammation, demyelination, and neuronal death in response to COVID-19. Interestingly, older adults with neurological dysfunction maintained on N-methyl-D-aspartate receptor (NMDAR) antagonists, such as memantine, had reduced incidence and severity of COVID-19. Thus, the present study aimed to evaluate (1) the neuroinflammatory response to COVID-19 in the respiratory centers of the brain, and (2) to assess the extent to which NMDAR antagonists offer neuroprotective measures in the context of COVID-19. In a susceptible mouse model, animals inoculated with SARS-CoV-2 were pre-treated with either memantine or an alternative NMDAR antagonist, ifenprodil. Inoculated animals had poor survival and showed signs of neuroinflammation, evidenced by a reduction in morphological structure, demyelination, and changes in astrocyte and microglial expression in the pons and medulla. Mice pre-treated with memantine showed improved survival when challenged with COVID-19 and a reduction in virus-induced neuroinflammatory impairments. Our findings support the further investigation of memantine for the prevention of COVID-19 induced neuroinflammation and resultant neurological symptoms and shed light on the possible protective mechanism of memantine in the elderly maintained on NMDAR antagonists.
1
COVID-19-related brainstem pathology included reduced morphological integrity, demyelination, and altered astrocyte and microglial expression.
2
Pre-treatment with memantine improved survival in SARS-CoV-2-challenged mice and reduced virus-induced neuroinflammatory impairments.
3
SARS-CoV-2 infection in susceptible mice caused poor survival and neuroinflammatory damage in the pons and medulla.
4
The findings support further investigation of memantine as a preventive treatment for COVID-19-associated neuroinflammation and neurological symptoms.
5
The study suggests a potential protective role of NMDAR antagonism in older adults receiving such medications.

SARS-CoV-2 infection in the pons and medulla of a susceptible mouse model

COVID-19-induced neuroinflammation, demyelination, neuronal damage, and survival, and their mitigation by NMDAR antagonists

Publication Details
Publication Date
2025-06-04
Journal
Publisher
ISSN
Cited by
3
Access Type
Author Information
Authors
Kenneth E. Palmer
Jon D. Gabbard
Linda P. Dwoskin
Jill R Turner
Emily R. Prantzalos
Jane P Chesser
Judy Songrady Logan
Kristen A. McLaurin
Charles D. Anderson
William E. Severson
Bobbi Jo Mullins
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%